The DEA has revoked the registration of a Philadelphia-based pharmacy for allegedly failing to comply with the agency’s controlled substance recordkeeping requirements (Just Here II Pharmacy; Decision and Order, 90 Fed. Reg. 31251 (July 14, 2025)).

The government alleged that between September 2023 and March 2024 Just Here II Pharmacy “failed to maintain accurate records of its inventory, purchasing and dispensing of controlled substances, in violation of federal and Pennsylvania law.”

Because of these failures, the government said, the pharmacy was unable to account for thousands of controlled substances during an accountability audit.

‘Significant Discrepancies’

For example, the pharmacy admitted to DEA officials that there were “significant discrepancies” between a dispensing report that agency investigators examined and the pharmacy’s distributor order data.

As the pharmacy acknowledged, a comparison of the dispensing record to the distributor order data revealed the following approximate discrepancies:

• 200 dosage units of oxycodone 4 HCL 5 mg;
• 1,459 dosage units of oxycodone HCL 15 mg;
• 430 dosage units of oxycodone HCL 20 mg;
• 287 dosage units of oxycodone-acetaminophen 5/325 mg;
• 440 dosage units of oxycodone-acetaminophen 10/325 mg;
• 654 dosage units of alprazolam 5 0.5 mg;
• 2,044 dosage units of alprazolam 1 mg;
• 2,930 dosage units of alprazolam 2 mg; and
• 2,839 dosage units of promethazine with codeine.

“These discrepancies amounted to a significant variance between [the pharmacy’s] dispensing data and distributor order for each substance, ranging from 33% to 100%,” the DEA said.

Default Determination

In an order to show cause and immediate suspension of registrations (OSC/ISO) issued to Just Here II Pharmacy in October 2024, the pharmacy was notified of its right to file with the DEA a written request for a hearing. The pharmacy was also notified that if it failed to request a hearing, it would be deemed to have waived its right to a hearing and to be in default.

In December 2024, the government requested that the DEA take final agency action by issuing a default final order revoking the pharmacy’s registration.

In not answering the allegations contained in the OSC/ISO and not otherwise availing itself of the opportunity to refute the government’s case, the DEA determined, the pharmacy had “made no representations as to its future compliance with the [Controlled Substances Act (CSA)] nor made any demonstration that it can be entrusted with registration.”

“Moreover,” the agency said, “the evidence presented by the government shows that [the pharmacy violated the CSA, further indicating that [the pharmacy] cannot be entrusted.”

On this basis, the DEA revoked the pharmacy’s registration, effective Aug. 13.